Compare IDE & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDE | HAE |
|---|---|---|
| Founded | 2010 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 3.9B |
| IPO Year | N/A | 1991 |
| Metric | IDE | HAE |
|---|---|---|
| Price | $14.02 | $57.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $86.00 |
| AVG Volume (30 Days) | 33.5K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-05-2026 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | ★ 43.84 |
| EPS | N/A | ★ 3.65 |
| Revenue | N/A | ★ $1,318,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.86 |
| P/E Ratio | ★ N/A | $15.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.61 | $47.32 |
| 52 Week High | $10.46 | $87.32 |
| Indicator | IDE | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 80.83 | 23.44 |
| Support Level | $13.23 | $55.95 |
| Resistance Level | $14.00 | $60.50 |
| Average True Range (ATR) | 0.14 | 2.35 |
| MACD | 0.03 | -0.58 |
| Stochastic Oscillator | 93.26 | 15.70 |
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.